Barrett Burke Thomas
Known title: President and CEOCIK: 0002023875
Barrett Burke Thomas's purchase track record
Barrett Burke Thomas has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/20/2024 | PLSE | $86K | +132.6% | +92.1% | +11.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PLSE | ▼ Sell | Open Market | 50,000 | $871K | 12/11/2024 | View on chart |
| PLSE | ▼ Sell | Other | 543 | $6K | 7/19/2024 | View on chart |
| PLSE | ▼ Sell | Other | 543 | $6K | 7/19/2024 | View on chart |
| PLSE | ▼ Sell | Other | 1,086 | — | 7/3/2024 | View on chart |
| PLSE | ▲ Buy | Open Market | 10,000 | $86K | 5/20/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Pulse Biosciences Partners with Clayman Thyroid Center
Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Additionally, Oppenheimer raised its price target to $60 and maintained an Outperform rating, citing the importance of the 2027 trial readout for the company's new ablation modality. The stock recently saw a 12.3% rise following the completion of full enrollment for the NANOPULSE-AF trial.
Pulse Biosciences Partners with Clayman Thyroid Center. Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Additionally, Oppenheimer raised its price target to $60 and maintained an Outperform rating, citing the importance of the 2027 trial readout for the company's new ablation modality. The stock recently saw a 12.3% rise following the completion of full enrollment for the NANOPULSE-AF trial.